Senseonics, Ascensia Diabetes Care Sign MoU for Eversense 365 CGM Transition

Senseonics Holdings, a medical technology company, has signed a Memorandum of Understanding with Ascensia Diabetes Care to take over commercialization and distribution of Eversense 365 CGM. The transition will occur from Ascensia Diabetes Care to Senseonics, and Brian Hansen will be appointed Chief Commercial Officer. Senseonics has also expanded its non-dilutive debt facility up to $100 million with Hercules Capital to fund the commercial organization. A conference call is scheduled for September 4, 2025, at 8:00 A.M. Eastern Time.